Abstract | Prolactin is best known for its actions on the mammary gland. However, circulating prolactin is also detected in males and its receptor (PRLR) is expressed in the prostate, suggesting that the prostate is a target of prolactin. Germline knockout of prolactin or its receptor has failed to reveal a key role for prolactin signaling in mouse prostate physiology. However, several studies involving rodent models and human prostate cell lines and specimens have supported the contribution of the canonical PRLR-Jak2-Stat5a/b pathway to prostate cancer tumorigenesis and progression. Increased expression of prolactin in the prostate itself (rather than changes in circulating prolactin levels) and crosstalk with androgen receptor (AR) signaling are potential mechanisms for increased Stat5a/b signaling in prostate cancer. In the mouse prostate, prolactin overexpression results in disorganized expansion of the basal/stem cell compartment, which has been proposed to house putative prostate tumor-initiating cells. These findings provide new insight into the molecular and cellular targets by which locally produced prolactin could contribute to prostate cancer initiation and progression. A number of pharmacological inhibitors targeting various levels of the PRLR-Jak2-Stat5a/b pathway have been developed and are entering clinical trials for advanced prostate cancer.
Introduction
Prolactin is a 23 kDa polypeptide hormone, which is found in all vertebrates, secreted mainly by the anterior pituitary. 1 The functions of prolactin are mediated by a non-kinase single-pass transmembrane receptor, PRLR. The PRLR is a member of the class 1 hematopoietic cytokine receptor superfamily that functions with various associated kinases. 2, 3 In mammals, the best studied and one of the main functions of prolactin is to stimulate lactation, a function mediated by the transcription factor Stat5a (signal transducer and activator of transcription 5a). Accordingly, mice carrying two null alleles of one of the genes encoding prolactin (PRL), PRLR (PRLR) or Stat5a (STAT5A) are unable to lactate owing to a failure of lobuloalveolar differentiation of the mammary epi thelium. [4] [5] [6] In humans, the mammary gland is also considered a major target tissue of prolactin-pharmacological blockade of pituitary prolactin production using dopamine agonists stops lactation in nursing mothers and, conversely, galactorrhea is one of the clinical symptoms of hyperprolactinemia.
Circulating prolactin is also detected in males, although it is present at lower levels than in females. However, its physiological role in males remains unclear. Based on the functional pleiotropy of prolactin suggested from the analysis of various experimental models, it is reasonable to propose that the role of prolactin in males involves some of its 'secondary' functions, which are mostly regulatory but not essential. These functions include modulation of the immune response, regulation of pancreatic β-cell mass, lipid metabolism and hair growth, to name but a few. 3, [7] [8] [9] [10] The prolactin responsiveness of prostate tissue was first proposed in 1956 from studies investigating hormonal control of prostate growth in castrated rats. 11 During the next four decades, studies in animal models suggested that prolactin participates in the normal development, growth and function of the prostate gland. 12 The discovery that human prostate expresses PRLR 13 demonstrated that this organ might be a direct target of prolactin. Notably, prolactin expression has been demonstrated in the prostate itself, 13 suggesting that this hormone might also act as a local growth factor via an autocrine or paracrine mechanism distinct from its classical endocrine route.
This novel view has driven various studies regarding the potential role of local prolactin in prostate cancer. Since 1973, it has been known that elevated circulating prolactin levels are not clearly linked to increased prostate cancer risk. 14 However, a growing number of connections has since emerged between prostate tumorigenesis and excess local prolactin production. This paradigm shift in our understanding of prolactin's action on the prostate is particularly important, because levels of local prolactin production in the prostate are much harder to evaluate clinically than circulating prolactin, and because the standard drugs (dopamine analogues) downregulating pituitary prolactin synthesis are assumed to be inefficient in regulating prolactin production in extrapituitary sites.
The past few years have been rich in studies deciphering the cellular and molecular mechanisms by which dysregulation of the PRLR signaling cascades participate in prostate tumorigenesis. The discovery that local overexpression of prolactin in the mouse prostate amplifies the pool of basal/stem cells, 15 which have been identified as originators of prostate cancer 16 and may mediate the prog ression to castrate-resistant prostate cancer (CRPC), has provided a mechanistic basis for the oncogenic potency of prolactin in prostate tissue. This Review will delineate the current understanding of the role of prolactin in prostate pathophysiology, with particular emphasis on cellular and molecular mechanisms 
Prolactin and prostate physiology
The role of prolactin in prostate physiology has been investigated almost exclusively in rodent models involving live intact or orchidectomized animals treated with dopamine agonists or prolactin. It was originally believed that the effects of prolactin on the prostate served merely to enhance androgen action [17] [18] [19] [20] [21] [22] [23] [24] and instigate secondary endocrinological changes. 25 This hypothesis was later disproved using organ cultures of normal and malignant prostate tissues, which demonstrated that prolactin directly stimulates proliferation 13, 26 and inhibits apop tosis of prostate epithelial cells, 27 instead of affecting prostate growth via other circulating hormones. The antiapoptotic and proliferative effects of prolactin are either direct and, most likely, Stat5-mediated, [28] [29] [30] or indirect, implying prolactin-induced expression of receptors for growth factors such as IGF-1 31 or androgen receptors. 24, 31 In addition, earlier studies suggested a stimulatory role for prolactin on epithelial secretion, function, energy metabolism and citrate production. 12 In agreement with the growth-promoting action of prolactin, mice lacking a functional prolactin gene (PRL -/-) have a reduced ventral prostate weight. 32 Conversely, the prostates of mice harbor ing two nonfunctional PRLR alleles 33 (PRLR -/-) displayed only minor histological defects (partial loss of epithelial content) and no growth or branching defects, whereas those lacking STAT5A displayed disorganized acini and altered secretory functions in ventral, but not other, prostate lobes. 34 Taken together, these various genetically-modified models failed to unanimously agree on a key role for PRLR signaling in prostate physiology, and more generally, in male reproductive function.
The paucity of data available on the role of prolactin in the normal human prostate has raised the question of the actual physiological function of prolactin in the human prostate. Although analysis of human prostate organ cultures indicated that prolactin induces growth and differentiation of prostate epithelium (as suggested by rodent studies), 13 extrapolations of data from animal models should be made very carefully, as prostate anatomy and morphology differ across species (Box 1). 35, 36 The discovery of dysfunctional mutations of PRL or PRLR in humans, provided they exist, should help clarify this issue.
Prolactin and prostate benign diseases
In contrast to the rather moderate consequences of downregulation of PRLR signaling on mouse prostate physio logy, upregulation of PRLR signaling has a more dramatic effect. The Mt-PRL transgenic mouse model, in which prolactin overexpression is driven from the neonatal period by the metallothionein promoter, demonstrated that prolactin is able to promote, either directly or indirectly, ductal morphogenesis in the developing prostate. 37 After a few weeks of prolactin over expression, prostates of Mt-PRL mice displayed classical features of The adult human prostate is a small acorn-shaped organ, with ductal-acinar histology that lacks discernible lobular organization. Three distinct morphological regions, the peripheral, transition and central zones, have been identified. In contrast to the anatomy of the human prostate, the mouse and rat prostate is composed of four paired lobes arranged circumferentially around the bladder and referred to as the dorsal, lateral, ventral and anterior lobes. Each lobe is anatomically distinct, but, owing to their small size and proximity to one another, the dorsal and lateral lobes are often examined together as the dorsolateral prostate. The dorsolateral prostate is considered analogous to the peripheral zone of human prostate, whereas the ventral lobe has no human equivalent. Thus, rodent models that develop cancers in the dorsolateral lobes are believed to be the most appropriate models for human prostate cancer. However, as evidence supporting human-rodent prostate analogies are primarily descriptive, this statement should be considered with caution, especially considering the fact that, unlike humans, mice never develop spontaneous prostate tumors. Besides anatomical differences, mouse and human prostates also differ at the histological level. Basal epithelial cells form a continuous layer in humans, while this layer is discontinuous in the mouse, with a 4:1 ratio of luminal:basal epithelial cells (Figure 1) . One of the hallmarks of human prostate cancer is the disappearance of basal cell markers, which is not observed in the mouse, where basal cells tend to adopt a distinct abnormal morphology and to form clusters. Neuroendocrine cells are even more rare in mouse than in human prostate. Finally, whereas the human prostate has a robust fibromuscular stroma, the latter is more loose in the mouse, where its density varies in each particular lobe and, in each lobe, on pericentral versus peripheral location.
benign prostate hyperplasia (BPH), including stromal hyper plasia and focal areas of epithelial dysplasia (prostate intra epithelial neoplasia; PIN). These effects were shown to be independent of elevated androgen levels. 38, 39 Prostate-specific expression of a PRL transgene at puberty using the probasin promoter (Pb-PRL mice) resulted in very similar phenotypes including dramatic hyper trophy of the three prostatic lobes (Box 1). 38 In rats, marked enlargement of the lateral prostate was observed when chronic hyperprolactinemia was induced using dopamine antagonists. 40 These data emphasize the importance of prolactin as a mitogen and growth promoter for rodent prostate epithelial cells. A similar proliferative effect of prolactin on human prostate epithelial cells was also reported using primary cultures derived from BPH specimens. 41 However, expression of PRLR was not increased in samples from patients with BPH compared with normal prostate samples. 42 Furthermore, small casecontrol studies failed to correlate circulating prolactin levels with BPH occurrence. 43 In addition, a prospective case-control study involving 20 hyper prolactinemic young men and 20 healthy controls concluded that prolactin excess had no effect on prostate volume-possibly because hyperprolactinemia is accompanied by low testosterone and DHT levels. 44 Finally, it is not currently known whether local autocrine prolactin expression is increased in BPH compared with the normal secretory human prostate epithelium. Thus, there is at present no strong argument supporting a role for prolactin in promoting BPH.
There is an increasing body of evidence supporting an association between chronic prostate inflammation (prostatitis) and BPH in men. 45, 46 It has even been proposed that BPH is an inflammatory disease, based on the observation that BPH nodules are often associated with chronic inflammatory infiltrates mainly composed of chronically activated T cells and macrophages. 47 Although a role for prolactin in human prostatitis has yet to be established, mild to moderate chronic inflammation involving lympho cyte and macrophage infiltrates has been reported in prostates of Pb-PRL transgenic mice, although the mechanisms underlying this phenotype are unknown. 15, 38 It has been suggested that prolactin mediates estrogen-induced prostate inflammation in rodents, 48, 49 and accordingly, inflammation was not observed in estrogen-deficient aroma tase knockout mice, despite the fact that they exhibited elevated levels of circulating prolactin. 50 These data suggest that elevated prolactin alone is not sufficient to exert proinflammatory effects. 50 Accordingly, the anti-inflammatory and antiestrogenic actions of androgens observed in a rat model of nonbacterially induced prostate inflammation were proposed to be partially mediated through decreased prolactin-induced responses. 51 Prolactin and prostate cancer: a local affair involving 144 men diagnosed with prostate cancer and 289 age-matched controls, concluded that elevated levels of circulating prolactin were not related to an increase in prostate cancer risk. This result was in agreement with previous studies investigating the levels of endogenous sex hormones in prostate cancer patients. 53, 54 Taken together, these papers suggested that endocrine pro lactin was not associated with the development of prostate cancer.
This finding was in apparent conflict with a wealth of data supporting a role for PRLR signaling in the promotion of prostate cancer in experimental models, specifically studies which demonstrated prolactininduced proliferation of human prostate cancer cell lines in vitro 55, 56 and xenograft tumors in vivo. 57 Additional evidence comes from genetically-modified mouse models, which demonstrated that the absence of PRLR expression (in a PRLR knockout model) reduced the incidence of simian virus 40 (SV40) T-induced prostate tumors. 33 Furthermore, systemic overexpression of prolactin in Mt-PRL mice led to androgen-independent prostate hypertrophy, including BPH and preneoplastic lesions. 37, 39 In conclusion, these data argued strongly that PRLR signaling plays a role in prostate tumorigenesis.
The lack of association between circulatory prolactin levels and incidence or progression of clinical prostate cancer in patients is likely to be due to high local autocrine prolactin production in human prostate cancer. As pituitary and extrapituitary prolactin share the same sequence, they are believed to exhibit the same efficacy towards the receptor. However, it is possible that local prolactin secreted directly into the extracellular space achieves elevated concentrations and saturates the PRLRs. Analysis of human prostate cancer specimens showed prolactin immunostaining in 54% of a series of 80 prostate cancer specimens, and was positively correlated with high Gleason scores and activation of Stat5a/b, its major signaling protein. 29 Furthermore, prolactin was also expressed in 50% of recurrent prostate cancer samples in a series of 183 specimens, 30 including hormone-refractory cancer (54% of positive cases) and those from patients with lymph node meta stases (67%). Finally, PRLR expression, as determined by in situ hybridization and immuno staining, was present in prostate cancer specimens, although it was more heterogeneously distributed in poorly differ entiated high-grade carcinoma than in low-grade tumors. 42 With respect to experimental models of human prostate cancer, prolactin mRNA expression was also detected in the CWR22Pc cell line (which can be used as a transplantable xenograft model and is assumed to closely mimic a clinical primary prostate tumor) as well as its castrate-resistant counterpart, CWR22R. 30 PRL is transcribed in numerous human prostate cancer cell lines including CWR22Rv, CWR22Pc, DU145, LNCaP and PC-3 and their xenografts, irrespective of androgen receptor status. 30 Expression of the PRLR was also detected in most of these cell lines, although at a lower level than that seen in breast cancer cell lines. 42, 58 Using various genetic and pharmaco logical approaches, the autocrine PRLR-Jak2-Stat5 cascade was demonstrated to be a critical survival pathway in CWR22R prostate cancer cell line, 30 in agreement with an earlier study that demon strated an antiapoptotic role of Stat5 in prostate cancer cells. 59 Overall, these observations indicate that an autocrine or paracrine loop of prolactin action is involved in prostate cancer progression, and the increased expression of PRLR in precancerous (dysplastic) lesions compared to normal prostate has led several groups to suggest the involvement of PRLR signaling in early stages of prostate cancer development. 42 Among the numerous differences between human and mouse prostate pathophysiology, mice never spontaneously develop prostate cancer. 60 Furthermore, although expression of endogenous prolactin in the mouse prostate has been suggested in one study based on mRNA amplification, 37 we are not aware of any report that has convincingly showed expression of prolactin protein, 15 all suggesting that an autocrine or paracrine mechanism may not be a predominant route of action of prolactin in the mouse prostate. Although it would be an overinterpretation to directly link these two observations, the potential importance of local prolactin in human prostate cancer etiology has prompted the development of the Pb-PRL mouse model harboring the autocrine/paracrine prolactin loop that may not intrinsically exist in mouse prostate. Prostate-specific expression of a prolactin transgene in Pb-PRL mice caused the development of BPH including preneoplastic lesions (PINs) 38 similar to those reported in Mt-PRL mice. These data suggest a mitogenic and antiapoptotic role for local prolactin in prostate epithelium. 37 In addition, our own group has shown that these lesions eventually evolve to invasive carci nomas in aged animals, indicating that over activation of PRLR signaling can result in malignancy, and not just benign disease. 15 Interestingly, comparison of different strains of Mt-PRL mice, which have different levels of circulating transgenic prolactin revealed that the circulating prolactin level had no impact on the features of their prostate tumors, stressing that locally produced (autocrine) prolactin is likely to be more efficient in promoting tumor growth than circulating (endocrine) prolactin.
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Mechanisms of tumor promotion by prolactin
Basal cell compartment as a local prolactin target A major discovery in the field of prostate cancer etiology was reported in 2010, when prostate basal cells were shown to serve as cells-of-origin for prostate cancer. 16 In this important study, Goldstein and colleagues introduced various genetic alterations commonly found in clinical prostate cancer into nonpathological human prostate basal cells, which were sorted based on putative stem cell surface markers. These alterations included over expression of Akt (an intracellular serine/threonine kinase with multiple signaling targets), ERG (a transcription factor whose gene is often translocated in prostate cancer), and the androgen receptor (AR). When grafted into immunodeficient mice, these genetically manipulated basal cells gave rise to tumors displaying multifocal and heterogeneous features similar to those observed in human disease. When manipulated identically, luminal cells were unable to generate tumors. 16 As one of the main features of human prostate cancer is the total loss of basal cell molecular markers in favor of exclusive expression of luminal markers, this result was somewhat unexpected. Interestingly, similar studies performed using basal and luminal cells of mouse origin achieved exactly the same conclusions, 61 confirming that rodents provide relevant experimental models to investigate how basal cells initiate prostate cancer in humans. However, it should be noted that a small population of luminal cells in mouse prostate, referred to as castrateresistant Nkx3.1-expressing cells, or CARNs, were also able to initiate cancer upon PTEN deletion. 62 Basal cells share the property of androgen-independence with late-stage CRPC cells, suggesting that pathways involved in basal cell function and self-renewal might also have a role in tumor cell survival and disease recurrence after androgen ablation. Interestingly, whereas p63-positive basal cells and those positive for stem cell antigen-1 normally localize within the central region of the gland, analysis of prostate tumors harbored by Pb-PRL mice showed dramatic accumulation and abnormal spreading of this basal cell compartment throughout the entire prostate gland. 15 Furthermore, colocalization of p63 with the proliferation marker KI67 indicated that proliferation was one of the mechanisms underlying basal cell expansion. However, there was no evidence for Stat5 activation in p63-positive cells, suggesting that the effect of prolactin on the basal compart ment might be indirect. The mechanistic rationale provided by this study supports the idea that the tumorigenic properties of constitutive PRLR signaling, coupled with its potential to promote hormonal escape, affects the basal cell compart ment (Figure 1 ).
The PRLR-Jak2-Stat5a/b pathway The PRLR lacks intrinsic enzymatic activity. In all tissues and cell types, it signals by activating various non-receptor tyrosine kinases. These include the canonical PRLR-Janus kinase 2 (Jak2)-Stat5a/b pathway (Box 2), the MAP kinase pathway, and the phosphoinositide 3-kinase (PI3K)-Akt, Src/Fyn and protein kinase C pathways. [63] [64] [65] [66] [67] [68] [69] [70] In contrast to breast cancer cells, in which activation of most, if not all, of these cascades has been documented, 71, 72 analysis of several human prostate cancer cell lines has suggested that prolactin stimulation does not activate Erk or Akt (M. T. Nevalainen, unpublished work). Whether MAPK/ Erk, PI3K-Akt, and various other signaling pathways contribute to PRLR signaling has yet to be conclusively ruled out, and, thus far, only Stat5a and Stat5b have been established as the key mediators of prolactin action in normal and malignant prostate tissue (Figure 2) . [28] [29] [30] Accordingly, Stat5 was the only classical component of the PRLR signaling pathways that was detectably activated in prostate tumors of Pb-PRL mice. 15 As short PRLR isoforms are unable to activate this pathway (Box 2), these findings imply that prolactin effects in the prostate are essentially mediated by long (and possibly intermediate) forms of the PRLR. For the purposes of this Review, therefore, "PRLR" refers to those isoforms of the receptor which lead to Stat5a/b phosphorylation and activation.
Stat proteins are a family of transcription factors that mediate cytokine and growth factor responses. [73] [74] [75] The repertoire of genes activated by prolactin depends largely on Stat5a/b binding to DNA. Although they are highly homologous, the 94 kDa Stat5a and 92 kDa Stat5b are distinct isoforms. [76] [77] [78] Once phosphorylated by Jak2 following PRLR activation (Box 2), Stat5a/b dimerizes and rapidly translocates to the nucleus. The available evidence has characterized the sequence of events leading to nuclear translocation as an energy-dependent process 79, 80 requiring interaction with Ran-dependent import machinery. 81, 82 Rac 1, a small G protein, MgcRacGAP, a chaperone protein, and β1-karyopherin/β1-importin, a carrier protein, cooperate to form a nuclear shuttling complex with the Stat5a/b dimer. 83 By contrast, unphosphorylated Stat proteins, which exist as monomers, are believed to shuttle freely at a high exchange rate between distinct nuclear and cytoplasmic pools, even in the absence of upstream cytokine signals. 79, 84 Nuclear-localized Stat5a/b binds to an 8-10 bp inverted repeat consensus sequence, TTC(C/T)N(G/A) GAA, known as the GAS (gamma-interferon activation sequence) element. Stat5a and Stat5b homo dimers possess equal binding affinity for half palindromes spaced 3 bp apart. Tetrameric binding of Stat proteins can occur in the presence of tandemly linked consensus (GAS) or nonconsensus motifs optimally spaced at 6 bp apart. . In this mouse model, luminal cells produce prolactin (purple) and express the PRLR (yellow), suggesting that proliferation of the luminal cell compartment might be mediated by direct autocrine or paracrine Stat5-mediated effects (1). The basal cell marker p63 does not colocalize with p-Stat5, suggesting that direct effects of prolactin on the basal cell compartment (green) could be mediated by signaling pathways other than Stat5 (2). Alternatively, indirect effects (3) could involve prolactin-induced production or secretion of putative growth factors from other tissue compartments, such as the stroma or prolactin-activated luminal cells. Although an effect of prolactin on human prostate basal cells has not been documented, similar mechanisms might be found in human prostate (right panels), as increased production of local prolactin and p-Stat5 have been correlated with Gleason score. One of the typical features of human prostate cancer is the loss of basal cell markers (p63) in favor of tumor makers. Otherwise, prolactin-induced tumors in the mouse prostate exhibited marked and disorganized amplification of the basal compartment, leading to clustering. Abbreviations: PIN, prostate intraepithelial neoplasia; PRL, prolactin; PRLR, prolactin receptor; p-Stat5: phosphorylated Stat5; Stat5, signal transducer and activator of transcription 5.
Stat5a/b in growth and clinical progression
The PRLR-Jak2-Stat5a/b pathway has been validated as a molecular target for the development of novel pharmaceutical therapies for prostate cancer. The relevance of active Stat5a/b to clinical prostate cancer progression is supported by evidence of its association with high histological grade 29 and ability to predict early disease recurrence. 87 To emphasize the predictive value of active Stat5a/b, it should be noted that subanalysis of intermediate Gleason grade prostate cancer samples still revealed Stat5a/b as an independent prognostic marker for early recurrent disease. 87 Furthermore, active Stat5a/b has been shown to critically regulate prostate cancer cell viability. Introduction of an adenovirally expressed dominant negative Stat5a/b mutant into cultured cells led to massive apoptosis, which was detectable using changes in cell morphology, metabolic cell viability assays, DNA fragmentation, and caspase 3 and caspase 9 activation. 59 Later work confirmed these initial findings by using inducible expression of a carboxy terminaltruncated Stat5b mutant-which inhibits both Stat5a and Stat5b-in cell lines derived from the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Expression of a mutant Stat5b reduced the ability of cells to grow in soft agar or form tumors in nude mice. 88 Work by Dagvadorj et al. 86 further supported the importance of active Stat5a/b in maintaining cell viability by using a variety of methodo logical approaches to inhibit Stat5a/b, which triggered massive cell death across numerous Stat5-positive prostate cancer cell lines. This same study extended the results to the in vivo setting by showing decreased incidence and growth of subcutaneous human prostate xenograft tumors in nude mice. 86 Intriguingly, it was recently found that Stat5a/b inhibition also induced rapid death of DU145 prostate cancer cells, which are AR-negative, indicating AR-independent effects of Stat5 on prostate cancer cell viability. 89 This result highlights the importance of evaluating the role of Stat5a/b in progression to the castrate-resistant stage of prostate cancer from multiple perspectives. One conceivable approach would be to investigate active Stat5a/b as a survival factor acting indepen dently of AR under castrate conditions, while another would be to look for possible enhancement of AR activity by Stat5a/b in the same setting.
Stat5a/b has emerged as a promoter of metastatic behavior of prostate cancer cells in vitro and in vivo. 90 Introduction of active Stat5 (Stat5aS710F) into DU145 prostate cancer cells before tail-vein injection into nude mice increased the formation of lung metastases from the cell suspension by 11-fold compared to unmodified DU145 cells. 89, 90 Moreover, active Stat5a/b is associated with increased cell migration, decreased cell-surface E-cadherin levels, and increased heterotypic adhesion of prostate cancer cells to endothelial cells, all hallmarks of the epithelial to mesenchymal transition that presages metastasis. 90 As further confirmation, cells from distant prostate cancer metastases and CRPC specimens were found to display increased nuclear-localized Stat5a/b and prolactin expression levels. 30, 91 In fact, in over 60% of metastatic prostate cancer clinical samples, Stat5a/b was found to be constantly active. 90 The mechanisms by which active Stat5a/b stimulates mobility, migration, and invasive ness of prostate cancer cells remain an area of active investigation. The implications of prolactin-PRLR-Jak2-Stat5a/b pathway involvement in prostate cancer development and progression, when coupled with the paucity of treatment options for patients with CRPC or metastatic disease, provides a strong rationale for targeting the prolactin signaling axis, either directly or via one of its downstream effectors.
Prolactin and androgen signaling crosstalk
The prolactin signaling pathway displays significant crosstalk with the AR signaling pathway in prostate cancer. CRPC is known to continually express AR, implying sustained activation of AR despite low levels of circulating androgens following androgen ablation therapy, 92 and the presence of active Stat5a/b in 95% of CRPC samples was recently highlighted. 92 Furthermore, it was demonstrated that activated Stat5a/b increased the transcriptional activity of AR, while ligand-bound AR, in turn, increased the transcriptional activity of Stat5a/b (Figure 2 ). This synergy between Stat5a/b and AR extended to a physical interaction between the two proteins, as detected by coimmunoprecipitation and double immunofluorescent staining, with both Stat5a/b and AR enhancing each other's nuclear localization in prostate cancer cells. 91, 93 Interestingly, software analysis has predicted the presence of GAS elements in the AR promoter region, suggesting possible recruitment of Stat5a/b to the AR promoter and a direct role for Stat5a/b in regulation Box 2 | The prolactin receptor
The human prolactin receptor (PRLR) is a transmembrane, single-pass, class I cytokine receptor, 2, 117, 118 encoded by the PRLR gene, which is located on chromosome 5p13-14. 119 In both rodents and humans, the PRLR gene can give rise to various PRLR isoforms, referred to simply as long, intermediate, and short. 71, 120, 121 Synthesized as precursors with a signal peptide of approximately 19-24 amino acids, all but one PRLR isoform contains identical extracellular domains (so-called ΔS1 PRLR lacks half of it) 71 and differ only in the length of their cytoplasmic tails. 2, 71, 120 The PRLR is N-glycosylated at three sites on its extracellular ligand-binding domain-Asn35, Asn80 and Asn108-which is crucial for proper trafficking of the receptor to the cell membrane. 122 The PRLR lacks intrinsic enzymatic activity, and is associated with the nonreceptor tyrosine kinase Jak2. 123 Upon prolactin binding, preformed PRLR homodimers are assumed to undergo conformational changes that enable Jak2 molecules associated with the receptor's cytosolic domain to move closer to each other, facilitating their activation by transphosphorylation. Subsequently, activated Jak2 phosphorylates key tyrosine residues of the PRLR cytoplasmic domain of long and intermediate isoforms. These phosphotyrosine motifs then act as docking sites for various signaling effectors, including Stat5a/b, typically via their SH2 domain. As the short PRLR isoforms are not tyrosine-phosphorylated, 3 they are believed to act as a dominant-negative on Stat5 activation. Following docking, Stat5a/b is rapidly phosphorylated by Jak2 at a conserved tyrosine residue in their C-terminus. Phosphorylation at Tyr694 and Tyr699 for Stat5a and Stat5b isoforms, respectively, leads to homodimerization or heterodimerization through phosphotyrosine-SH2 domain interactions between Stat monomers. 124, 125 Several protein kinases are capable of phosphorylating Stat proteins on serine residues, enabling further potentiation of the initial prolactin-mediated signals. 126 Interestingly, phosphorylation of Ser726 on Stat5a and Ser731 on Stat5b appears to have an inhibitory effect on transcriptional activity of these proteins. 85, 127, 128 REVIEWS of AR transcription (M. T. Nevalainen, unpublished work). Given that both Stat5a/b and AR act as growthpromoting transcription factors, it is highly plausible that their cooperative action could permit continued proliferation despite low levels of androgens, and support viability in conditions otherwise conducive to apoptosis. Further investigation is needed to dissect the molecular mechanisms of Stat5a/b-AR synergy, as well as to extend these findings to in vivo studies.
Therapeutic targeting of PRLR signaling
Organ-confined prostate cancer is amenable to surgery or local radiation therapy, whereas the treatment options for disseminated malignancy include radiation, hormone therapy and chemotherapy. 94 Unfortunately, the response to hormone therapy in the form of androgen ablation is of limited duration, and late-stage disease inevitably recurs as CRPC, for which there is no curative treatment.
Pharmacological inhibitors of PRLR
Historically, the primary antiprolactin drugs have been dopamine agonists, which block pituitary prolactin expression and secretion by triggering the D2 dopamine receptor (D2R) on lactotroph cells. 95, 96 However, the efficacy of this class of drugs in regulating the prolactin gene in the human prostate (as in other extrapituitary sources) has yet to be demonstrated, and, based on the fact that D2R expression has only been occasionally reported in human prostate samples, 97, 98 they are anticipated to be ineffective for targeting extrapituitary prolactin expression. In the absence of the availability of potent neutralizing anti-PRLR monoclonal antibodies, PRLR antagonists are a logical therapeutic choice, given their ability to block autocrine prolactin action in various cell types. 8, 30, 99, 100 The competitive PRLR antagonist G129R-PRL 101 and its second-generation analogue, Δ1-9-G129R-hPRL 30, 95 (a pure PRLR antagonist lacking the residual agonism that characterizes G129R-hPRL), provide a promising means of pharmacological inhibition of PRLR signaling. Notably, Rouet and colleagues 15 have published a proofof-concept study for the use of a pure PRLR antagonist to prevent early prostate tumorigenesis initiated by local prolactin. Indeed, the hallmarks of prostate tumorigenesis observed in Pb-PRL transgenic mice (such as hyper trophy, expansion of a putative tumor-initiating cell population, and constitutive Stat5 activation) were all prevented when Pb-PRL mice were crossed with another transgenic strain that ubiquitously expressed Δ1-9-G129R-hPRL. 15 Ongoing studies are working towards improving the pharmacokinetics of the recombinant Δ1-9-G129R-hPRL compound, which should be possible by conjugation to polyethylene glycol moieties or carrier proteins. 102 Whereas competitive receptor antagonists are designed to block functional PRLR dimerization, another means of achieving PRLR blockade is via the use of pseudophosphorylated prolactin (S179D-hPRL). Rather than exerting an antagonistic effect at the receptor, the S179D-hPRL variant stimulates production of the short PRLR isoform (SF1b), which is hypothesized to act in a dominant negative capacity to decrease PRLR-Stat5a/b signaling. 103 However, the molecular mechanisms underlying the induction of alternative splicing of the PRLR are not known.
Despite the fact that these compounds have been available for some time, direct anti-PRLR therapy has yet to be employed in the clinic. Currently, competitive antagonists are assumed to prevent activation of all PRLR isoforms as they all share the same extracellular ligand-binding domain. Also, there is no evidence that their inhibitory effect is selective for particular signaling cascades activated by PRLR in various target tissues. Thus, any PRLR-mediated function in any tissue could be affected, and the systemic consequences of such PRLR blockade in humans are not known. However, it is of note that PRLR-deficient mice do not show any clinically apparent signs of metabolic disorder, toxicity or lethality. 4 The absence of any unexpected phenotype in transgenic mice that express the pure antagonist Δ1-9-G129R-hPRL suggests that PRLR-specific competitive antagonists might not have major off-target effects. 15 However, caution is required-a study by Frank and colleagues 104 revealed that the promiscuity of the PRLR with the growth hormone receptor led to versatile efficacy of PRLR antagonists in breast and prostate cancer cells, which was dependent on the PRLR agonist competed (prolactin or growth hormone)and the relative level of expression of these two closely related receptors. With respect to the alternative PRLR agonist S179D-hPRL, the potential systemic outcome of its administration to patients is currently unpredictable, as transgenic mice expressing this variant have yet to be generated.
Pharmacological inhibitors of Jak2
Constitutive activation of Jak2 is conferred by an activating somatic mutation involving the JH2 pseudokinase domain, V617F, which can lead to the development of a number of myeloproliferative disorders (MPDs), including polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. 105 The V617F mutation has also been found in acute myeloid leukemias (AMLs), occurring at a low rate in de novo AML and more frequently in AML which develops following a preceding MPD. 106, 107 Indeed, persistent Stat3 activation associated with hyperactive Jak2 V617F has been found to be oncogenic. 75 Consequently, Jak2 inhibitors were first developed in the context of hematopoietic malignancies. Although V617F was recently determined to be absent in both locally confined prostate cancer and CRPC, 108 the concept of Jak2 inhibition still holds promise in disrupting aberrant prolactin signaling (Figure 2) .
The compound WP1066, which is also known as (E)-3(6-bromopyridin-2-yl)-2-cyano-N-(S0-1-phenylethyl) acrylamide, was one of the first compounds to demonstrate effective inhibition of Jak2 phosphorylation, and, accordingly, inhibition of downstream phosphorylation of Stat3, Stat5, and Akt. 109 Interestingly, WP1066 also led to degradation of Jak2, providing yet another means for attenuating the effects of Jak2. Incubation of several AML cell lines with the compound ultimately resulted in caspase-dependent cell death.
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AZD1480 is a potent pyrazolyl pyrimidine developed to function as a small-molecule competitive ATP inhibitor of Jak2 (K i = 0.26 nM). In addition to inhibiting the growth of a panel of cancer cell lines in vitro, nude mice bearing DU145 (prostate), MB-MDA-468 (breast), and MDAH2774 (ovarian) human xenograft tumors demonstrated reduced tumor volume and abrogated Stat3 activity when treated with AZD1480, compared with control mice treated with vehicle. 110 The demonstration that AZD1480 blocks oncogenesis in solid tumors validates Jak2 inhibition as a rational pharmacological approach in treatment of prostate cancer.
As with many kinase inhibitors, selectivity is a concern; for example, evaluation of AZD1480 against a panel of 82 kinases, selected to represent the diversity of the kinome, demonstrated that 11 kinases were inhibited by greater than 50% at 0.10 μM. 110 Given the potential for non specific inhibition, combined with the fact that other cytokines signal through Jak family kinases (for example, IL-6 via Stat3), it will be necessary to optimize the dosing in order to avoid off-target toxicity. 110 Pharmacological inhibitors of Stat5a/b Stat5a/b has emerged as an attractive target for rational drug design in prostate cancer. Theoretically, Stat dimerization can be inhibited by targeting the SH2 domain, transactivation can be inhibited by targeting the C-terminal transactivation domain and DNA binding can be blocked by targeting the DNA-binding domain.
Early work in this area highlighted the feasibility of disrupting Stat5 transcriptional activity by using decoy oligonucleotides, which mimic Stat5a/b binding sites, to sequester Stat5a/b from its target genes. Sequestration of Stat5a/b successfully inhibited cyclin D1 expression in NRK-49F kidney cells. 111 Building on this approach, it was later shown that peptide aptamers selected from combinatorial libraries were capable of blocking Stat5a/b binding to DNA, as well as Stat5a/b dimerization. 112 A variety of methods to downregulate Stat5a/b have now been characterized, including a dominant-negative mutant lacking the transactivation domain, 59 ,86 antisense oligonucleotides and RNA interference. 86 Finally, phosphotyrosyl peptides or peptidomimetics, which bind the SH2 domain, effectively inhibited Stat3 dimerization, 113, 114 but these studies did not investigate whether this strategy also applied to Stat5. All the strategies to inhibit Stat5a/b that have been investigated require further development before clinical application. Similar to Jak2 inhibitors, there is a concern regarding offtarget effects of Stat5 inhibition on hematopoietic 115 and immune cell development. 116 Overcoming these obstacles will be of prime importance in bringing Stat5a/b-targeted therapeutics to the clinic. Nonetheless, the continued development of compounds to produce small molecule inhibitors of Stat5a/b promises to expand the available armamentarium for treating prostate cancer, hopefully in the near future.
Conclusions
Prolactin has recently entered the limited panel of nonandrogenic signaling pathways that are emerging as potential candidates for targeted therapy in a subset of prostate cancer patients. Indeed, evidence has accumulated within the past few years to suggest that activation of Stat5, the downstream effector of the canonical PRLR signaling pathway, has a key role in prostate cancer progression. Interestingly, locally produced prolactin of prostate origin, rather than circulating prolactin secreted by the pituitary, seems to be the biochemical source for activation of the pathway, and might, therefore, represent another relevant target in PRLR-Jak2-Stat5a/b signaling pathway. The available data raise several important questions for translating these findings from bench to bedside: what additional evidence is required to advance the development of targeted therapies for prolactin and its signaling cascade? Will the analysis of PRLR-Jak2-Stat5a/b activation status provide a routinely employed diagnostic tool to guide the clinical management of prostate cancer? If so, which measure of PRLR signaling will be most rele vant to disease statusprolactin expression levels, Stat5 phosphosylation, or another marker? And perhaps most importantly, which therapeutic approach will ultimately prove most effective in downregulating over-activated PRLR signaling in patients selected for targeted therapy? These are the key challenges to be addressed in future research.
Review criteria
In addition to the combined reference databases of the Goffin and Nevalainen laboratories (containing ~6,000 articles), we searched PubMed for original and review publications with no date restriction, using various combinations of the terms "prolactin", "prostate", "cancer", "hyperplasia", "prostatitis", "dopamine agonist" and "hyperprolactinemia". All papers identified were fulltext papers in English. We also searched the reference lists of identified articles for further relevant papers.
